Bread for celiac vaccine
ImmusanT banks $20M based on celiac immunotherapy's T cell response
Bread for celiac vaccine
ImmusanT Inc. is working on a peptide-based therapeutic vaccine designed to address the underlying problem in celiac disease, and received $20 million in
